Ryan Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan Huang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Cheng Zhang
University of Texas Southwestern Medical Center 1 Department of Physiology Dallas, Texas
26 shared publications - Cheryl Lewis
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
26 shared publications - Xiaoye Liu
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX, USA
26 shared publications - Caroline Smith
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
25 shared publications - Jingjing Xie
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas
25 shared publications - Ningyan Zhang
Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, 1825 Pressler Street, Houston, TX 77030, USA
25 shared publications
Latest Publications
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF17
Leukocyte Immunoglobulin-Like Receptor A3 Inhibits the Activity of Immunosuppressive Myeloid Cells
Myeloid checkpoint blockade as monotherapy often yields limited benefit, suggesting that multiple inhibitory pathways cooperatively sustain myeloid immunosuppression in the tumor microenvironment. However, strategies to concurrently target multiple myeloid checkpoints remain challenging. Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble LILRA/B family member with unclear immunoregulatory function. In this study, we show that LILRA3 is significantly reduced in the serum and tumor tissues of patients with cancer, and its systemic levels positively correlate with cytotoxic T-cell infiltration and improved survival. LILRA3 suppresses immunosuppressive myeloid cells, enhances proinflammatory cytokine production, and inhibits M2 macrophage polarization, thereby indirectly promoting T-cell proliferation. Mechanistically, LILRA3 binds to LILRB4 and multiple endogenous LILRB ligands, blocking downstream inhibitory signaling. LILRA3 restrains tumor growth in myeloid-specific LILRB2- and LILRB4-transgenic mice and in humanized mouse models. These findings identify LILRA3 as a natural multi-LILRB signaling antagonist that counteracts myeloid-driven immunosuppression and highlight its potential as a therapeutic immune modulator.
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF17
Leukocyte Immunoglobulin-Like Receptor A3 Inhibits the Activity of Immunosuppressive Myeloid Cells
Myeloid checkpoint blockade as monotherapy often yields limited benefit, suggesting that multiple inhibitory pathways cooperatively sustain myeloid immunosuppression in the tumor microenvironment. However, strategies to concurrently target multiple myeloid checkpoints remain challenging. Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a soluble LILRA/B family member with unclear immunoregulatory function. In this study, we show that LILRA3 is significantly reduced in the serum and tumor tissues of patients with cancer, and its systemic levels positively correlate with cytotoxic T-cell infiltration and improved survival. LILRA3 suppresses immunosuppressive myeloid cells, enhances proinflammatory cytokine production, and inhibits M2 macrophage polarization, thereby indirectly promoting T-cell proliferation. Mechanistically, LILRA3 binds to LILRB4 and multiple endogenous LILRB ligands, blocking downstream inhibitory signaling. LILRA3 restrains tumor growth in myeloid-specific LILRB2- and LILRB4-transgenic mice and in humanized mouse models. These findings identify LILRA3 as a natural multi-LILRB signaling antagonist that counteracts myeloid-driven immunosuppression and highlight its potential as a therapeutic immune modulator.
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eadt7832
Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer
The mechanisms underlying tumor cell–myeloid cell interactions in the tumor microenvironment (TME) remain unclear, and predictive biomarkers for patient response to myeloid checkpoint blockade are lacking. This study identified specific binding between tight junction claudins (CLDNs) and leukocyte immunoglobulin-like receptor subfamily B2 (LILRB2) and LILRB5. In multiple human cancer cohorts, the spatial proximity of LILRB2-positive macrophages to CLDN-expressing cancer cells correlated with clinical outcomes, highlighting this spatial relationship as a potential biomarker. In syngeneic LILRB2-transgenic and humanized mouse models, CLDN18.2-LILRB2 interactions triggered bidirectional signaling, enhanced the immunosuppressive activity of myeloid cells, and accelerated tumor progression. These effects were reversed by LILRB2 blockade. The CLDN-LILRB2 axis sustained immunosuppression by regulating NF-κB and STAT signaling pathways. Our findings reveal a mechanism of myeloid cell regulation by tight junction proteins in the TME, offering a rationale for targeting this pathway in cancer therapy.
- 3 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eadt7832
Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer
The mechanisms underlying tumor cell–myeloid cell interactions in the tumor microenvironment (TME) remain unclear, and predictive biomarkers for patient response to myeloid checkpoint blockade are lacking. This study identified specific binding between tight junction claudins (CLDNs) and leukocyte immunoglobulin-like receptor subfamily B2 (LILRB2) and LILRB5. In multiple human cancer cohorts, the spatial proximity of LILRB2-positive macrophages to CLDN-expressing cancer cells correlated with clinical outcomes, highlighting this spatial relationship as a potential biomarker. In syngeneic LILRB2-transgenic and humanized mouse models, CLDN18.2-LILRB2 interactions triggered bidirectional signaling, enhanced the immunosuppressive activity of myeloid cells, and accelerated tumor progression. These effects were reversed by LILRB2 blockade. The CLDN-LILRB2 axis sustained immunosuppression by regulating NF-κB and STAT signaling pathways. Our findings reveal a mechanism of myeloid cell regulation by tight junction proteins in the TME, offering a rationale for targeting this pathway in cancer therapy.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S1. Eph receptors do not bind to LILRB1, LILRB3, LILRB4 and LAIR1.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S1. Eph receptors do not bind to LILRB1, LILRB3, LILRB4 and LAIR1.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Immunosuppressive myeloid cells are critical obstacles to T cell–centered immune checkpoint blockade therapies, which have been successful in treating a fraction of patients with cancer. How tumor cells interact with myeloid cells to regulate immune responses and tumor development is unclear. In this study, we report that certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and LILRB2. These Eph receptors induce LILRB5-mediated signaling activation, and LILRB5 also activates Eph receptor signaling. Activation of LILRB5 promoted immunosuppressive marker expression and inhibited activating marker expression on myeloid cells from patients with cancer in vitro. Upon myeloid cell–specific expression of LILRB5 in transgenic mice, the interaction between the Eph receptor on tumor cells and LILRB5 on myeloid cells led to increased tumor growth, increased immunosuppressive myeloid cells, and decreased frequencies of functional T cells compared with control mice. Eph-induced LILRB5 signaling and functions were reversed by LILRB5 blockade. In sum, certain Eph receptors functionally interact with the myeloid checkpoint receptor LILRB5 resulting in bidirectional signaling, and LILRB5 plays an important role in supporting immunosuppressive myeloid cells and sustaining tumor development.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Immunosuppressive myeloid cells are critical obstacles to T cell–centered immune checkpoint blockade therapies, which have been successful in treating a fraction of patients with cancer. How tumor cells interact with myeloid cells to regulate immune responses and tumor development is unclear. In this study, we report that certain membrane tyrosine kinase Eph receptors, including EphA7 and EphB1, specifically bind the immune inhibitory receptors leukocyte Ig-like receptor family B 5 (LILRB5) and LILRB2. These Eph receptors induce LILRB5-mediated signaling activation, and LILRB5 also activates Eph receptor signaling. Activation of LILRB5 promoted immunosuppressive marker expression and inhibited activating marker expression on myeloid cells from patients with cancer in vitro. Upon myeloid cell–specific expression of LILRB5 in transgenic mice, the interaction between the Eph receptor on tumor cells and LILRB5 on myeloid cells led to increased tumor growth, increased immunosuppressive myeloid cells, and decreased frequencies of functional T cells compared with control mice. Eph-induced LILRB5 signaling and functions were reversed by LILRB5 blockade. In sum, certain Eph receptors functionally interact with the myeloid checkpoint receptor LILRB5 resulting in bidirectional signaling, and LILRB5 plays an important role in supporting immunosuppressive myeloid cells and sustaining tumor development.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S6. EphB1 expression on tumor cells promotes T cell exhaustion in LILRB5 transgenic mice.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S6. EphB1 expression on tumor cells promotes T cell exhaustion in LILRB5 transgenic mice.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S2. LILRB5-ECD induces EphB1 phosphorylation.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S2. LILRB5-ECD induces EphB1 phosphorylation.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S3. EphB1 activates LILRB5 in vitro and promote immune suppressive functions.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S3. EphB1 activates LILRB5 in vitro and promote immune suppressive functions.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S4. Myeloid specific transgenic mice of LILRB5.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S4. Myeloid specific transgenic mice of LILRB5.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S5. EphA7 overexpression on LLC cells supports tumor growth in myeloid-specific LILRB5 transgenic mice.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development
Fig. S5. EphA7 overexpression on LLC cells supports tumor growth in myeloid-specific LILRB5 transgenic mice.